Elmiron® (pentosan polysulfate sodium), a commonly prescribed blood-thinning medication has been on the market since 1996. Created by Janssen Pharmaceuticals, Elmiron is used to treat interstitial cystitis (aka. painful bladder syndrome). Recent studies from the Emory Eye Center in Atlanta, Georgia, Kaiser in Oakland, California, Harvard Medical School, and more have found a direct link between Elmiron Patients and serious retinal maculopathy.
Elmiron patients may not know they have a macular disorder, and instead, just assume their vision is degrading due to old age or other reasons. This disorder can cause eye pain, blurry vision, difficulty reading, and even blindness. Elmiron can cause retinal maculopathy even after stopping use of this drug.
Elmiron has not yet been recalled by the Food and Drug Administration (FDA).
- Difficulty reading
- Difficulty acclimating to dim lighting
- Dark spots usually at center vision
- Muted or dull colors
- Blurry vision
- Straight lines become curved
- Eye Pain
Plaintiffs in Elmiron lawsuits accuse Janssen Pharmaceuticals of failing to properly warn the public about the risk of vision problems. Recent studies linked interstitial cystitis (IC) drug, also known as pentosan polysulfate sodium (PPS), to ocular toxicity and irreversible vision damage.